AI brief of an SEC Form 8-K · IMPACT BIOMEDICAL INC. (IBO)

Impact Biomedical says SEC declared Zoar merger registration effective; vote set for Nov. 13

Neutral Impact 4 of 5 m&a Written later

Impact Biomedical announced that the SEC declared effective on October 23, 2026, the Form F-4 registration statement for its proposed business combination with Zoar Limited. Impact stockholders will vote on the merger at a special meeting on November 13, 2026, and closing remains subject to that vote and NYSE American listing approval. The filing does not include financial results, so the effect on shareholder value cannot be assessed from it.

Key points

SEC declared the Form F-4 effective on October 23, 2026; proxy materials mailed the same day
Special stockholder meeting scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard Time
Combined company expected to trade on NYSE American as ZOAR, subject to listing approval
Company states there can be no assurance the business combination will be completed on any particular timetable or at all

The filing

CompanyIMPACT BIOMEDICAL INC. (IBO)

Form8-K, current report

Filed with the SECNov 3, 2026, 9:15 AM ET

Accession number0001493152-26-049727

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.